Some survivors of childhood cancer are more at risk for serious health issues as they grow older, including new cancers and chronic conditions like heart disease, according to a study published in the Journal of Clinical Oncology.
The MammaPrint, a gene expression profiling test, predicts the benefit of chemotherapy for patients with hormone receptor-positive, HER2-negative early-stage breast cancer, according to findings published in JNCI Cancer Spectrum.
ELI-002 2P, an off-the-shelf cancer vaccine, can trigger powerful and lasting immune responses, and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, according to a study published in Nature Medicine.
KU Cancer Center has launched an investigator-initiated trial designed to attack three different targets on cancer cells at once. “The Triple Threat” approach is designed to boost CAR T-cell therapy’s chances of destroying blood cancers.
Cancer cells can break down the protective covers around nerves, causing nerve injury that triggers chronic inflammation leading to immune exhaustion and eventual resistance to immunotherapy, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.
The Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity, according to findings by University College London and Veracyte, Inc., a genomic diagnostic company.
Many people with advanced cancer report that their treatment does not align with their personal care goals, according to a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and the UCLA Palliative Care Research Center.
Cylembio (imsapepimut and etimupepimut, adjuvanted), an off-the-shelf therapeutic cancer vaccine, plus pembrolizumab narrowly missed on its primary endpoint of progression free survival for patients with unresectable or metastatic melanoma, according to phase III trial results.
Mailing a stool-based test directly to people’s homes was the most effective of four strategies for increasing colorectal cancer screening rates, according to a study by UCLA researchers aimed at identifying the best approach to promote CRC screening in adults ages 45 to 49.
EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.
